Our Company

Cell>Point is a late stage Phase 3 biotech company whose principal disease focus is cancer, cardiovascular, neuroendocrine, diabetes and ischemia. The company is developing new products and technologies for innovative molecular theragnostic approaches in these diseases. Since its founding, Cell>Point has in-licensed five technology platforms from The University of Texas M.D. Anderson Cancer Center (M.D. Anderson).

The company’s lead drug product is a derivative of ethylenedicysteine-glucosamine (trademarked as “Oncardia®”) which can be labeled with either 99mTc or 68Ga for nuclear imaging, complexed with platinum or Rhenium-187 for intra-nuclear metallic therapy, or can be labeled with Rhenium-188 or Lutetium-177 for intra-nuclear radiotherapy. Cell>Point is completing a Phase 3 lung cancer imaging trial for 99mTc-Oncardia® under an FDA approved Special Protocol Assessment (“SPA”), and a Phase 2b trial for 99mTc-Oncardia® to diagnose the presence and extent of coronary artery disease focusing specifically on myocardial ischemia in patients who have suffered a myocardial infarction. In therapy, the company is completing preclinical studies on its first two compounds, platinum-Oncardia® and 187Re-Oncardia®, for the treatment of patients with relapsed aggressive diffuse type B-cell lymphoma.

Other Cell>Point compounds in preclinical development include the DTPA-sulfonylurea compound 99mTc-DTPA-Nateylinide to image the pancreas and quantify beta cell activity; N4 compound for neuroendocrine tumor and CNS imaging and therapy and In-Situ Hydrogel for local regional therapy for liver, prostate, melanoma, pancreatic, kidney, brain and lung tumors. Cell>Point and its lead product 99mTc-Oncardia® have been featured on Fox News, Fox Business Channel, National Public Radio and local affiliates of ABC, CBS and NBC.

Cell>Point is privately held with offices in Colorado and Texas.

SENIOR MANAGEMENT

GREG COLIP

Founder, Managing Member & CEO

Greg Colip is a founding member of Cell>Point, the CEO and has been providing financial support to the company since its beginning. Mr. Colip brings over 38 years experience in health care marketing and legal. Prior to establishing the company with Jerry Bryant and Terry Colip, Mr. Colip was a corporate mergers and acquisition lawyer and served as Deputy General Counsel for Panhandle Eastern Corporation (which has since been split up with part of the company’s subsidiaries owned by Duke Energy and the remaining part owned by CMS Energy), provided legal counsel and development work for various independent power projects, served as Vice President and General Counsel for the Gulfco Division of Chromalloy American Corporation and was a production/marketing manager for The Upjohn Company (now part of Pharmacia). At Panhandle Eastern, Mr. Colip was involved in numerous complex venture, merger, spin-off and acquisition transactions including the $2.4 billion acquisition of Texas Eastern Corporation and the $1.2 billion drop down and spin-off of Anadarko Petroleum Corporation. At Upjohn, Mr. Colip was production/marketing systems manager for the corticosteriod and anticoagulant product lines. Mr. Colip received a B.S. in production management/industrial engineering in 1970, a M.B.A. in 1972 and a J.D. in 1978 from Indiana University.

TERRY COLIP

Founder, Managing Member & CFO

Terry Colip is a founding member of Cell>Point, the CFO and has been providing financial support to the company since its beginning. Mr. Colip brings 26 years experience in health care investment banking and venture capital. Prior to the establishment of Cell>Point, Mr. Colip provided equity and investment banking services for approximately $2 billion in health care transactions at Underwood Neuhaus & Co., Boettcher & Co and American Health Capital, Inc. and worked as a healthcare consultant for Coopers & Lybrand in New York. Mr. Colip was also a founding partner of Chewton Glen Energy L.L.C which developed two large electric power generation facilities in Illinois. Mr. Colip has been featured by many media outlets, including Fox Business Network, Fox News, NBC News Denver, ABC News Denver, CBS News Denver and National Public Radio. Mr. Colip received a B.S.I.E. from the College of Engineering at University of Wisconsin in 1979 and a M.P.A. in finance and health care administration from New York University in 1981. Mr. Colip dedicates his time and support to charities and organizations in health care and outreach for the disabled.

Jerry Bryant, Jr.

Founder, Managing Member & CTO

Jerry Bryant, Jr., is a founding member of Cell>Point, the CTO and has been providing financial support to the company since its beginning. Mr. Bryant is also President and Managing Member of Vyripharm Biopharmaceuticals, a majority owned subsidiary of Cell>Point. Mr. Bryant brings 15 years in research experience in molecular biology, imaging and oncology. Prior to the establishment of Cell>Point, Mr. Bryant worked as a research assistant from 1994 through 1999 in the Department of Medicine, Division of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center. During 1999 and 2000, Mr. Bryant served as President of Allcure JEMA, Inc. Mr. Bryant received his B.S. from Tennessee State University in 1987 and M.S. from the University of Florida in 1991.

David Yang, PhD.

Vice President, Research

Dr. Yang brings to the Company more than 30 years of pharmaceutical and fine chemicals experience. Dr. Yang received his B.S. degree in Pharmacy from Taipei Medical University in 1978. In 2007, Dr. Yang was promoted to Professor with tenure and also appointed to be the Chief of Radiotheranositc at the Division of Diagnostic Imaging at the University of Texas MD Anderson Cancer Center (UTMDACC). Dr. Yang’s research is involved in image-guided personalized treatment and prevention in cancers. Dr. Yang has mentored many clinic fellows, post-doctors, and UTGSBS students to their terminal Ph.D. degree. He received Distinguished Mentor Award for post-doctors in February, 2009 and Trainee Research Mentor Award by the MD Anderson Alumni and Faculty Association in May, 2010. He retired from UTMDACC in August, 2014, but holds the Consultant at the UTHSC, Houston, TX. At present, Dr. Yang is the Vice President for Vyripharm Biopharmaceuticals (Houston, TX). He also holds Visiting Professor both at the Department of Radiology in Yokohama City University in Japan and Taipei Medical University in Taiwan.

F. DAVID ROLLO

F. DAVID ROLLO, M.D., PH.D., FACC, FACNP

Consultant – Former President

Dr. Rollo joined Cell>Point in September 2006 and now serves aa a consultant to the company. Prior to Cell>Point, Dr. Rollo was Chief Medical Officer for Philips Medical Systems (now Philips Healthcare). Prior to joining Philips, Dr. Rollo served as Senior Vice President for Medical Affairs and Executive Medical Director for Raytel Medical Corporation from June 1996 to October 1999. Raytel owned and managed 15 outpatient diagnostic imaging centers and two hospital-based cardiovascular centers. From January 1995 to June 1996, Dr. Rollo served as Senior Vice President for Medical Affairs of HCIA following the sale of his ownership in Metricor (a healthcare company that had been spun off from Humana to HCIA). Metricor was a provider of quality management and clinical outcome services, technology assessment and asset management services and billing, coding and collections consulting services. During this same period of time, Dr. Rollo served as President of Managed Medical Imaging, a company specializing in outsourcing management of diagnostic imaging services for hospitals. With Humana, Dr. Rollo served as Chief Medical Officer and as Senior Vice President for Medical Affairs. He was also the founding Medical Director of the Humana Health Plans. He has received nearly 60 awards, honors and grants and has held over 40 professional appointments. Dr. Rollo’s clinical and research activities focused on non-invasive diagnostic procedures to include echocardiography, nuclear imaging, PET imaging, digital angiography and vascular imaging for CT and MRI. Dr. Rollo’s education includes a Master of Science in Radiological Physics from University of Miami, a Ph.D. in Physics from the Johns Hopkins Medical Institutions and an M.D. from Upstate Medical Center in Syracuse. Dr. Rollo is a Fellow of the American College of Cardiology, a Fellow of the American College of Nuclear Physicians, is Board Certified by the American Board of Nuclear Medicine and Cardiology. Dr. Rollo has served on the Board of Directors of 11 companies, five of which went public.

logolink2city

Link2City

Link2City is the industry leader in e-business development. We help businesses utilize Internet technology to increase revenue. Our broad suite of integrated marketing and website development services are designed to build brands and increase companies’ bottom lines. We design websites that are marketing- and sales-driven. We optimize site code to maximize search engine exposure and develop back-end applications to maximize site usability and reduce operation overhead.

Cell>Point’s Board of Directors include leaders of the nuclear medicine community.  Cell>Point staffs its clinical trial work and research through consulting and sponsored research agreements representing approximately 65 full time equivalents (FTE’s).